A real-world study of diverse RC48-based regimens across disease stages of urothelial carcinoma
Bladder · 2025
DOI: 10.14440/bladder.0169 ↗Santrauka
Background: RC48, a human epidermal growth factor receptor 2 (HER2)-targeting antibody–drug conjugate (ADC), has been approved in China for the treatment of HER2-positive metastatic urothelial carcinoma. Objective: This study evaluated the efficacy and safety of various RC48-based regimens in patients with urothelial carcinoma across disease stages in real-world settings. Methods: We retrospectively analyzed data from 56 patients at different disease stages who were treated at the Second Hospital of Lanzhou University between March 2023 and June 2024. RC48-ADC was administered as a monotherapy or in combination with immunotherapy until discontinuation due to disease progression, intolerable toxicity, death, or other reasons. Results: Outcomes included the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). The median patient age was 67.5 years, with 83.9% being male. Of all patients, 14 (25.0%) received RC48-ADC monotherapy, and 42 (75.0%) received RC48-ADC combined with immunotherapy. Response rates were as follows: 15 patients (26.8%) achieved complete remission, 21 (37.5%) attained partial remission, 14 (25.0%) had stable disease, and 6 (10.7%) suffered from disease progression. The overall ORR was 64.3%, with rates of 70.0% and 60.0% in first-line and second-line treatment groups, respectively. The median PFS lasted for 6 months (range: 5–7 months), whereas the median OS was not reached. The most common TRAEs were peripheral sensory neuropathy (58.9%), fatigue (48.2%), decreased appetite (42.9%), and weight loss (37.5%). Conclusion: No increased incidence of TRAEs was observed in patients with poor performance status or impaired kidney function. RC48-ADC demonstrated efficacy and safety in patients with urothelial carcinoma, providing clinical benefits regardless of performance status or renal function.
EUVIMED